|
Video: What is a Stock Split?
|
|
AnaptysBio is a clinical stage biotechnology company developing immunology therapeutic product candidates focused on immune control mechanisms applicable to inflammation and immuno-oncology indications. Co.'s wholly-owned antibody programs include: imsidolimab, which inhibits the interleukin-36 receptor and is being developed for the treatment of multiple dermatological inflammatory diseases; rosnilimab, which is an anti-PD-1 agonist antibody program designed to augment PD-1 signaling via rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, which is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. According to our AnaptysBio stock split history records, AnaptysBio has had 0 splits. | |
|
AnaptysBio (ANAB) has 0 splits in our AnaptysBio stock split history database.
Looking at the AnaptysBio stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AnaptysBio shares, starting with a $10,000 purchase of ANAB, presented on a split-history-adjusted basis factoring in the complete AnaptysBio stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/27/2017 |
|
End date: |
05/02/2024 |
|
Start price/share: |
$17.53 |
|
End price/share: |
$26.34 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
50.26% |
|
Average Annual Total Return: |
5.77% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$15,029.52 |
|
Years: |
7.26 |
|
|
|
|
|